ARDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ARDX is a mixed but not ideal buy right now for a beginner long-term investor with $50,000-$100,000, especially since the user wants a decision now and is not waiting for a better entry. The business is improving operationally and the analyst outlook is bullish, but the stock has no proprietary buy signal, hedge funds are selling, and the short-term price setup is not compelling enough to call it an immediate buy.
ARDX is in a short- to medium-term uptrend technically, with SMA_5 above SMA_20 above SMA_200, which is bullish. MACD is positive at 0.112, but the histogram is positively contracting, suggesting momentum is fading rather than accelerating. RSI_6 at 67.257 is near the upper end of neutral and close to overbought territory. Price at 7.00 is sitting just below resistance at 7.22, with support at 6.605. The technical picture is constructive, but not strong enough to justify an aggressive entry today, especially given the bearish next-day/next-week pattern statistics.
["Q1 2026 product revenue of $93.4 million, up 38% year over year", "Latest financial snapshot shows revenue growth of 27.47% YoY in Q1 2026", "Gross margin improved to 94.91%, showing strong product economics", "CFO reiterated 2026 IBSRELA revenue guidance of $410 million to $430 million", "New patent announced with expiration in November 2042, which H.C. Wainwright highlighted positively", "New ACCEL trial initiated for IBSRELA in chronic idiopathic constipation, providing a future catalyst", "Analyst price target raised to $18 from $10 while maintaining a Buy rating"]
["Hedge funds are selling, with selling up 129.11% over the last quarter", "Net income remains negative at -$37.6 million", "EPS remains negative at -0.15", "MACD momentum is positive but contracting", "RSI is near overbought levels, limiting near-term upside from current prices", "Pattern analysis suggests downside over the next day, week, and month", "No AI Stock Picker signal today", "No SwingMax entry signal recently", "No recent congress trading data available", "Post-close price action was only mildly positive at 0.29%, with the stock still down on the regular session"]
In Q1 2026, Ardelyx showed strong top-line growth with revenue rising to $94.47 million, up 27.47% year over year, and reported product revenue of $93.4 million, up 38% year over year. Gross margin improved sharply to 94.91%, which is a strong sign of business quality. The main weakness is profitability: net income was -$37.61 million and EPS was -0.15, both still negative. Overall, the latest quarter season was growth-positive but not yet profitable.
Recent analyst trend is positive. On 2026-02-20, H.C. Wainwright raised its price target on Ardelyx to $18 from $10 and maintained a Buy rating, citing encouragement from the new patent extending to November 2042. Wall Street pros appear constructive because of revenue growth, improving margins, patent protection, and guidance confidence. The main con view is that the company is still losing money, and the current stock action does not yet confirm strong follow-through despite the bullish target increase.
